Topline data from the Phase 3 PALISADE study (NCT05089084) in patients with familial chylomicronaemia syndrome (FCS) have shown that the apolipoprotein C3 (APOC3) inhibitor, plozasiran, significantly reduced median TG levels by up to -80% at month 10, with mean reductions in APOC3 of up to -94%.
